Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)
調査の概要
詳細な説明
PRIMARY OBJECTIVES:
I. To assess the efficacy and safety of the combination of rituximab, cladribine, and temsirolimus for newly diagnosed mantle cell lymphoma.
II. To determine the maximum tolerated dose (MTD) of temsirolimus combined with a fixed dose and schedule of rituximab and cladribine. (Phase I) III. To assess the efficacy of the combination of rituximab, cladribine, and temsirolimus for newly diagnosed mantle cell lymphoma with the proportion of complete responses as the primary endpoint. (Phase II)
SECONDARY OBJECTIVES:
I. To assess other measures of efficacy of the regimen including progression free survival, duration of response, and overall survival.
II. To assess the toxicity profile of the combination of rituximab, cladribine, and temsirolimus.
III. To assess efficacy using traditional lymphoma parameters and absolute lymphocyte count.
IV. To assess metabolic markers (hyperglycemia, hyperlipidemia) as markers of mammalian target of rapamycin (mTOR) inhibition using the glucose and lipid measurements being performed in the clinical laboratory as part of routine care.
V. To correlate response with serum free light chains, single nucleotide polymorphisms (SNPs) in host immune genes, vitamin D metabolites, and phosphatidylinositide 3-kinase (PI3K) pathway member expression.
VI. As part of ongoing research for North Central Cancer Treatment Group (NCCTG) lymphoma studies, paraffin-embedded tissue blocks/slides and blood products will be banked for future studies.
OUTLINE: This is a phase I, dose-escalation study of temsirolimus followed by a phase II study.
Patients receive rituximab intravenously (IV) on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim subcutaneously (SC) on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 4 months for 3 years.
研究の種類
入学 (予想される)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Arizona
-
Scottsdale、Arizona、アメリカ、85259-5499
- Mayo Clinic Scottsdale
-
-
Illinois
-
Bloomington、Illinois、アメリカ、61701
- Illinois CancerCare - Bloomington
-
Bloomington、Illinois、アメリカ、61701
- St. Joseph Medical Center
-
Canton、Illinois、アメリカ、61520
- Illinois CancerCare - Canton
-
Canton、Illinois、アメリカ、61520
- Graham Hospital
-
Carthage、Illinois、アメリカ、62321
- Memorial Hospital
-
Carthage、Illinois、アメリカ、62321
- Illinois CancerCare - Carthage
-
Eureka、Illinois、アメリカ、61530
- Illinois CancerCare - Eureka
-
Eureka、Illinois、アメリカ、61530
- Eureka Community Hospital
-
Galesburg、Illinois、アメリカ、61401
- Illinois CancerCare - Galesburg
-
Galesburg、Illinois、アメリカ、61401
- Galesburg Clinic, PC
-
Havana、Illinois、アメリカ、62644
- Mason District Hospital
-
Havana、Illinois、アメリカ、62644
- Illinois CancerCare - Havana
-
Kewanee、Illinois、アメリカ、61443
- Illinois CancerCare - Kewanee Clinic
-
Macomb、Illinois、アメリカ、61455
- Illinois CancerCare - Macomb
-
Macomb、Illinois、アメリカ、61455
- Mcdonough District Hospital
-
Monmouth、Illinois、アメリカ、61462
- Illinois CancerCare - Monmouth
-
Monmouth、Illinois、アメリカ、61462
- OSF Holy Family Medical Center
-
Normal、Illinois、アメリカ、61761
- Bromenn Regional Medical Center
-
Normal、Illinois、アメリカ、61761
- Community Cancer Center
-
Normal、Illinois、アメリカ、61761
- Illinois CancerCare - Community Cancer Center
-
Ottawa、Illinois、アメリカ、61350
- Community Hospital of Ottawa
-
Ottawa、Illinois、アメリカ、61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin、Illinois、アメリカ、61554
- Cancer Treatment Center at Pekin Hospital
-
Pekin、Illinois、アメリカ、61603
- Illinois CancerCare - Pekin
-
Peoria、Illinois、アメリカ、61636
- Methodist Medical Center of Illinois
-
Peoria、Illinois、アメリカ、61614
- Proctor Hospital
-
Peoria、Illinois、アメリカ、61637
- OSF St. Francis Medical Center
-
Peoria、Illinois、アメリカ、61615
- CCOP - Illinois Oncology Research Association
-
Peoria、Illinois、アメリカ、61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru、Illinois、アメリカ、61354
- Illinois CancerCare - Peru
-
Peru、Illinois、アメリカ、61354
- Illinois Valley Community Hospital
-
Princeton、Illinois、アメリカ、61356
- Perry Memorial Hospital
-
Princeton、Illinois、アメリカ、61356
- Illinois CancerCare - Princeton
-
Spring Valley、Illinois、アメリカ、61362
- Illinois CancerCare - Spring Valley
-
-
Indiana
-
Elkhart、Indiana、アメリカ、46515
- Elkhart General Hospital
-
Elkhart、Indiana、アメリカ、46514-2098
- Elkhart Clinic, LLC
-
Elkhart、Indiana、アメリカ、46514
- Michiana Hematology-Oncology, PC - Elkhart
-
Kokomo、Indiana、アメリカ、46904
- Howard Community Hospital
-
La Porte、Indiana、アメリカ、46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
Mishawaka、Indiana、アメリカ、46545-1470
- Michiana Hematology-Oncology, PC - South Bend
-
Mishawaka、Indiana、アメリカ、46545-1470
- Saint Joseph Regional Medical Center
-
Plymouth、Indiana、アメリカ、46563
- Michiana Hematology Oncology PC - Plymouth
-
South Bend、Indiana、アメリカ、46601
- Memorial Hospital of South Bend
-
South Bend、Indiana、アメリカ、46601
- CCOP - Northern Indiana CR Consortium
-
Westville、Indiana、アメリカ、46391
- Michiana Hematology Oncology PC - La Porte
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic, PC
-
Cedar Rapids、Iowa、アメリカ、52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids、Iowa、アメリカ、52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Clive、Iowa、アメリカ、50325
- Medical Oncology and Hematology Associates - West Des Moines
-
Des Moines、Iowa、アメリカ、50309
- CCOP - Iowa Oncology Research Association
-
Des Moines、Iowa、アメリカ、50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines、Iowa、アメリカ、50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines、Iowa、アメリカ、50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines、Iowa、アメリカ、50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Mason City、Iowa、アメリカ、50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
Sioux City、Iowa、アメリカ、51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City、Iowa、アメリカ、51102
- Mercy Medical Center - Sioux City
-
Sioux City、Iowa、アメリカ、51104
- St. Luke's Regional Medical Center
-
-
Kansas
-
Chanute、Kansas、アメリカ、66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City、Kansas、アメリカ、67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado、Kansas、アメリカ、67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott、Kansas、アメリカ、66701
- Cancer Center of Kansas - Fort Scott
-
Independence、Kansas、アメリカ、67301
- Cancer Center of Kansas-Independence
-
Kingman、Kansas、アメリカ、67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence、Kansas、アメリカ、66044
- Lawrence Memorial Hospital
-
Liberal、Kansas、アメリカ、67901
- Cancer Center of Kansas, PA - Liberal
-
Newton、Kansas、アメリカ、67114
- Cancer Center of Kansas, PA - Newton
-
Parsons、Kansas、アメリカ、67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt、Kansas、アメリカ、67124
- Cancer Center of Kansas, PA - Pratt
-
Salina、Kansas、アメリカ、67401
- Cancer Center of Kansas, PA - Salina
-
Wellington、Kansas、アメリカ、67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita、Kansas、アメリカ、67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita、Kansas、アメリカ、67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita、Kansas、アメリカ、67214
- CCOP - Wichita
-
Wichita、Kansas、アメリカ、67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita、Kansas、アメリカ、67208
- Associates in Womens Health, PA - North Review
-
Winfield、Kansas、アメリカ、67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Battle Creek、Michigan、アメリカ、49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids、Michigan、アメリカ、49307
- Mecosta County Medical Center
-
Escanaba、Michigan、アメリカ、49431
- Green Bay Oncology, Limited - Escanaba
-
Grand Rapids、Michigan、アメリカ、49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids、Michigan、アメリカ、49503
- CCOP - Grand Rapids
-
Grand Rapids、Michigan、アメリカ、49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Iron Mountain、Michigan、アメリカ、49801
- Dickinson County Healthcare System
-
Muskegon、Michigan、アメリカ、49443
- Mercy General Health Partners
-
Niles、Michigan、アメリカ、49120
- Michiana Hematology Oncology PC - Niles
-
Saint Joseph、Michigan、アメリカ、49085
- Lakeside Cancer Specialists, PLLC
-
Saint Joseph、Michigan、アメリカ、49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
Wyoming、Michigan、アメリカ、49519
- Metro Health Hospital
-
-
Minnesota
-
Burnsville、Minnesota、アメリカ、55337
- Fairview Ridges Hospital
-
Coon Rapids、Minnesota、アメリカ、55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth、Minnesota、アメリカ、55805
- CCOP - Duluth
-
Duluth、Minnesota、アメリカ、55805-1983
- Duluth Clinic Cancer Center - Duluth
-
Duluth、Minnesota、アメリカ、55805
- Miller - Dwan Medical Center
-
Edina、Minnesota、アメリカ、55435
- Fairview Southdale Hospital
-
Fridley、Minnesota、アメリカ、55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson、Minnesota、アメリカ、55350
- Hutchinson Area Health Care
-
Maplewood、Minnesota、アメリカ、55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood、Minnesota、アメリカ、55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis、Minnesota、アメリカ、55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis、Minnesota、アメリカ、55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale、Minnesota、アメリカ、55422-2900
- Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic Cancer Center
-
Saint Louis Park、Minnesota、アメリカ、55416
- CCOP - Metro-Minnesota
-
Saint Louis Park、Minnesota、アメリカ、55416
- Park Nicollet Cancer Center
-
Saint Paul、Minnesota、アメリカ、55102
- United Hospital
-
Saint Paul、Minnesota、アメリカ、55101
- Regions Hospital Cancer Care Center
-
Shakopee、Minnesota、アメリカ、55379
- St. Francis Cancer Center at St. Francis Medical Center
-
Stillwater、Minnesota、アメリカ、55082
- Lakeview Hospital
-
Waconia、Minnesota、アメリカ、55387
- Ridgeview Medical Center
-
Willmar、Minnesota、アメリカ、56201
- Willmar Cancer Center at Rice Memorial Hospital
-
Woodbury、Minnesota、アメリカ、55125
- Minnesota Oncology Hematology, PA - Woodbury
-
-
Montana
-
Billings、Montana、アメリカ、59101
- CCOP - Montana Cancer Consortium
-
Billings、Montana、アメリカ、59101
- St. Vincent Healthcare Cancer Care Services
-
Billings、Montana、アメリカ、59107-7000
- Billings Clinic - Downtown
-
Billings、Montana、アメリカ、59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman、Montana、アメリカ、59715
- Bozeman Deaconess Cancer Center
-
Butte、Montana、アメリカ、59701
- St. James Healthcare Cancer Care
-
Great Falls、Montana、アメリカ、59405
- Great Falls Clinic - Main Facility
-
Great Falls、Montana、アメリカ、59405
- Sletten Cancer Institute at Benefis Healthcare
-
Havre、Montana、アメリカ、59501
- Northern Montana Hospital
-
Helena、Montana、アメリカ、59601
- St. Peter's Hospital
-
Kalispell、Montana、アメリカ、59901
- Kalispell Regional Medical Center
-
Kalispell、Montana、アメリカ、59901
- Glacier Oncology, PLLC
-
Kalispell、Montana、アメリカ、59901
- Kalispell Medical Oncology at KRMC
-
Missoula、Montana、アメリカ、59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Dakota
-
Bismarck、North Dakota、アメリカ、58501
- Bismarck Cancer Center
-
Bismarck、North Dakota、アメリカ、58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck、North Dakota、アメリカ、58501
- Mid Dakota Clinic, PC
-
Bismarck、North Dakota、アメリカ、58502
- St. Alexius Medical Center Cancer Center
-
-
South Dakota
-
Rapid City、South Dakota、アメリカ、57701
- Rapid City Regional Hospital
-
-
Wisconsin
-
Green Bay、Wisconsin、アメリカ、54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay、Wisconsin、アメリカ、54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay、Wisconsin、アメリカ、54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay、Wisconsin、アメリカ、54303
- St. Mary's Hospital Medical Center - Green Bay
-
Manitowoc、Wisconsin、アメリカ、54221-1450
- Holy Family Memorial Medical Center Cancer Care Center
-
Marinette、Wisconsin、アメリカ、54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Oconto Falls、Wisconsin、アメリカ、54154
- Green Bay Oncology, Limited - Oconto Falls
-
Sheboygan、Wisconsin、アメリカ、53081
- St. Nicholas Hospital
-
Sturgeon Bay、Wisconsin、アメリカ、54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
-
Wyoming
-
Sheridan、Wyoming、アメリカ、82801
- Welch Cancer Center at Sheridan Memorial Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically confirmed mantle cell lymphoma (MCL); the diagnosis must be confirmed by NCCTG pre-registration pathology review by Dr. Paul Kurtin or his designate; it is recommended that the biopsy be an excisional biopsy, but adequate core-needle biopsies will be accepted as long as they are considered adequate for registration by Dr. Kurtin or his designate; the tumor must be cyclin D-1 positive by immunohistochemistry or have evidence of a t(11;14) translocation by fluorescence based in situ hybridization (FISH) or cytogenetics
Measurable or assessable disease, defined as at least one of the following:
- A lymph node or tumor mass that is >= 2.0 cm in at least one dimension by positron emission tomography (PET)/computed tomography (CT), CT, magnetic resonance imaging (MRI), or plain radiograph imaging
- Splenic enlargement may be used as a measurable parameter if the spleen is palpable >= 3 cm below the left costal margin
- Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral blood, liver, lungs, or bowel by lymphoma without a discrete mass would constitute assessable, but not measurable, disease
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2, or 3
- Life expectancy >= 12 weeks
- Absolute neutrophil count (ANC) >= 1,500/mm³
- Platelet count (PLT) >= 100,000/mm³
- Serum creatinine =< 2.0 mg/dL
- Serum total bilirubin (or direct bilirubin if total is abnormal) =< institutional upper limit of normal (ULN) with or without secondary liver involvement
- Serum glutamic oxaloacetic transaminase (SGOT) =< 3 x institutional ULN (exception: if there is liver involvement, SGOT must be =< 5 x institutional ULN)
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Willingness to return to NCCTG enrolling institution for follow-up
- Willingness to provide the blood specimens as required by the protocol
- Willingness to provide tissue specimens as required by the protocol
- Willing to return to NCCTG enrolling institution for follow-up
- Willing to provide blood and tissue specimens as required by the protocol
- Willing to abstain from eating grapefruit or drinking grapefruit juice
- Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study
Exclusion Criteria
- Any prior therapy for mantle cell non-Hodgkin lymphoma including radiation therapy; exception: patient may have undergone a splenectomy for diagnosis, cytopenia, or systematic splenomegaly
- Active or uncontrolled infection
Any of the following cardiac conditions:
- Uncontrolled high blood pressure
- Unstable angina
- Active congestive heart failure
- Myocardial infarction =< 6 months
- Serious uncontrolled cardiac arrhythmia
- Known central nervous system (CNS) involvement
Any of the following:
- Pregnant women or women of reproductive ability who are unwilling to use effective contraception while taking the drug and for 12 months after stopping treatment
- Nursing women
- Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 12 months after stopping treatment
- Medical or psychiatric conditions which, in the opinion of the investigator, make the patient a poor risk for participation
- Known to be human immunodeficiency virus (HIV) positive; HIV testing is not required but should be done if clinically indicated; HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study
- Concurrent malignancy =< 5 years ago; exceptions: carcinoma in situ of the cervix, resected basal cell or squamous cell carcinomas of the skin, or prostate cancer that is in remission following a radical retropubic prostatectomy or radiation therapy; if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
- Known hypersensitivity to rituximab or its components, or to murine proteins
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
- Prior treatment with an mTOR inhibitor
- Autologous or allogeneic stem cell transplant planned as part of initial therapy
- Receiving enzyme-inducing antiepileptic drugs (enzyme inducing anti-epileptic drugs [EIAEDs]; e.g., phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, phenobarbital, or primidone); any other potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer such as rifampin, glucocorticoids at greater than adrenal replacement levels, or St. John's wort; or receiving strong CYP3A4 inhibitors * Note: if these agents are discontinued, temsirolimus therapy can begin >= 7 days after discontinuation of such agent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (rituximab, cladribine, temsirolimus)
Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5.
Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6.
Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Give IV
Give IV
Give IV
Give SC
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Number of dose limiting toxicity incidents as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 3.0 (Phase I)
時間枠:28 days
|
28 days
|
|
Proportion of complete tumor responses defined as complete remission (CR) as the objective status (Phase II)
時間枠:Up to 5 years
|
Up to 5 years
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
全生存
時間枠:最長5年
|
最長5年
|
|
生存時間
時間枠:5年まで
|
5年まで
|
|
Progression-free survival (PFS)
時間枠:up to 5 years
|
up to 5 years
|
|
Time to disease progression
時間枠:up to 5 years
|
up to 5 years
|
|
Duration of response, defined as date at which the patient's objective status is first noted to be either a CR or partial remission to the date progression is documented
時間枠:Up to 5 years
|
Up to 5 years
|
|
Frequency and severity of adverse events assessed by CTCAE v3.0
時間枠:Up to 5 years
|
Up to 5 years
|
協力者と研究者
捜査官
- スタディチェア:David J. Inwards, MD、Mayo Clinic
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- NCCTG-N078D
- NCI-2009-00669 (レジストリ識別子:CTRP (Clinical Trials Reporting System))
- CDR0000619329 (レジストリ識別子:PDQ (Physician Data Query))
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。